# US 2008/0305111 A1 · Anti-C35 antibodies for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305111 A1
- Document ID: US20080305111A1
- Status: Published application
- Kind: A1
- Application number: 11/812,996
- Filed: 2007-06-22
- Published: 2008-12-11
- Earliest claimed: 2006-06-22
- Assignees: Vaccinex, Inc.
- Inventors: Elizabeth E. Evans; Mark J. Paris; Deepak M. Sahasrabudhe; Maurice Zauderer; Ernest S. Smith
- Web page: https://patentgrep.com/patent/US20080305111A1

## CPC

- C07K 16/30: from tumour cells
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.

## Claims

### Claim 1

A method of killing cancer cells that express C35, the method comprising administering to said cells (a) a first C35 antibody or antigen binding fragment thereof that specifically binds C35; (b) a second C35 antibody or antigen binding fragment thereof that specifically binds C35; and (c) a therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein said method is performed in vivo.

### Claim 3 (depends on 2)

The method of claim 2, wherein said method is performed in a mammal.

### Claim 4 (depends on 3)

The method of claim 3, wherein said mammal is a human.

### Claim 5 (depends on 1)

The method of claim 1, wherein said first and second C35 antibodies or fragments each bind to a different C35 epitope.

### Claim 6 (depends on 1)

The method of claim 1 wherein at least one of said first or second C35 antibodies or fragments binds a C35 epitope selected from the group consisting of a C35 epitope located within amino acid residues 105-115 of SEQ ID NO:2, a C35 epitope located within amino acid residues 48-87 of SEQ ID NO:2, and a C35 epitope located within amino acid residues 48-104 of SEQ ID NO:2.

### Claim 7 (depends on 1)

The method of claim 1, wherein said therapeutic agent is a chemotherapeutic agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, adriamycin, docetaxel, taxotere, gemcitabine, and vinorelbine.

### Claim 9 (depends on 8)

The method of claim 8, wherein said chemotherapeutic agent is paclitaxel.

### Claim 10 (depends on 8)

The method of claim 8, wherein said chemotherapeutic agent is adriamycin.

### Claim 11 (depends on 1)

The method of claim 1, wherein said therapeutic agent is administered prior to administering at least one of said first or second C35 antibodies.

### Claim 12 (depends on 1)

The method of claim 1, wherein said therapeutic agent is administered after administering at least one of said first or second C35 antibodies.

### Claim 13 (depends on 1)

The method of claim 1, wherein said therapeutic agent is administered concurrently with at least one of said first or second C35 antibodies.

### Claim 14 (depends on 1)

The method of claim 1, wherein said first and second C35 antibodies are administered concurrently.

### Claim 15 (depends on 1)

The method of claim 1, wherein said first and second C35 antibodies are administered sequentially.

### Claim 16 (depends on 1)

The method of claim 1, wherein each of said C35 antibodies or fragments is administered at a dose of about 0.1 mg/kg to about 100 mg/kg of a patient's body weight.

### Claim 17 (depends on 1)

The method of claim 1, wherein at least one of said first or second C35 antibodies or fragments is selected from the group consisting of 1F2, 1B3, MAbc0009, MAb 163, MAb 165, MAb 171, and variants or derivatives thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein one of said first or second C35 antibodies or fragments is MAb 163 or a variant or derivative thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein one of said first or second C35 antibodies or fragments is 1B3 or a variant or derivative thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein one of said first or second C35 antibodies or fragments is 1F2 or a variant or derivative thereof.

### Claim 21 (depends on 17)

The method of claim 17, wherein said first and second C35 antibodies are selected from the group consisting of 1F2, 1B3, MAbc0009, MAb 163, MAb 165, MAb 171, and variants or derivatives thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein said first and second C35 antibodies are 1B3 and 1F2 or variants or derivatives thereof.

### Claim 23 (depends on 1)

The method of claim 1, wherein the cancer cells are selected from the group consisting of breast cancer, liver cancer, ovarian cancer, bladder cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer, and melanoma.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer cells are breast cancer cells.

### Claim 25 (depends on 23)

The method of claim 23, wherein the cancer cells are liver cancer cells.

### Claim 26 (depends on 1)

The method of claim 1, wherein said method comprises administering more than two C35 antibodies or fragments thereof.

### Claim 27

An isolated antibody or antigen-binding fragment thereof which specifically binds to the same C35 epitope as the reference antibody MAb 163.

### Claim at position 28

28-48. (canceled)

### Claim 49 (depends on 27)

A composition comprising the antibody or fragment thereof of claim 27, and a carrier.

### Claim at position 30

50-111. (canceled)

### Claim 112

An isolated polynucleotide comprising a nucleic acid sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the MAb 163 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35.

### Claim at position 32

113-117. (canceled)

### Claim 118 (depends on 112)

A vector comprising the polynucleotide of claim 112.

### Claim at position 34

119-125. (canceled)

### Claim 126 (depends on 112)

A composition comprising the polynucleotide of claim 112.

### Claim at position 36

127-149. (canceled)

### Claim 150 (depends on 112)

A host cell comprising the polynucleotide of claim 112.

### Claim 151

(canceled)

### Claim 152 (depends on 150)

A method of producing an anti-C35 antibody or antigen-binding fragment thereof, comprising culturing the host cell of claim 150, and recovering said antibody or fragment.

### Claim 153 (depends on 152)

An anti-C35 antibody, or antigen-binding fragment thereof, produced by the method of claim 152.

### Claim 154

An isolated polypeptide comprising an immunoglobulin heavy chain variable region (VH), wherein the CDR1, CDR2, and CDR3 regions of said VH are identical respectively, except for fewer than 10 amino acid substitutions, to reference heavy chain CDR1, CDR2, and CDR3 sequences consisting of SEQ ID NO:63, SEQ ID NO:64, and SEQ ID NO:65, and wherein an antibody or antigen-binding fragment thereof comprising said VH specifically binds to C35.

### Claim at position 42

155-180. (canceled)

### Claim 181 (depends on 154)

A composition comprising the polypeptide of claim 154, wherein an antibody or antigen-binding fragment thereof comprising said VH specifically binds to C35.

### Claim at position 44

182-198. (canceled)

### Claim 199 (depends on 154)

An isolated antibody or antigen binding fragment thereof comprising the polypeptide of claim 154.

### Claim 200 (depends on 49)

A method for treating cancer comprising administering to an animal suffering from cancer an effective amount of the composition of claim 49.

### Claim at position 47

201-202. (canceled)

### Claim 203

A composition comprising: (a) a first C35 antibody that specifically binds to C35; (b) a second C35 antibody that specifically binds to C35; and (c) a therapeutic agent.

### Claim at position 49

204-209. (canceled)

### Claim 210 (depends on 27)

A method of detecting the presence of C35, the method comprising: (a) contacting a sample or cell with an antibody or antigen binding fragment thereof according to claim 27; and (b) detecting the binding of said antibody or antigen binding fragment thereof to C35.

### Claim at position 51

211-213. (canceled)

### Claim 214

An isolated antibody or antigen binding fragment thereof comprising at least one, two, three, four, five or six CDRs of the MAb 163 monoclonal antibody, wherein said antibody or fragment specifically binds C35.

### Claim at position 53

215-220. (canceled)
